Table 1: Patients characteristics and transplantation details (N = 51).

Characteristics Cases
N = 51 (%)
Healthy Controls
(Peripheral blood donors)
N = 35 (%)
P Value
Gender
Female
Male

24 (47%)
27 (53%)

16 (46%)
19 (54%)

P > 0.05
Age (years) Median (range): 36 (16-69)
< = 20
21-40
> 40

07 (14%)
22 (43%)
22 (43%)

03 (09%)
19 (54%)
13 (37%)

P > 0.05
Diagnosis
AML, ALL, ABL, MDS
HL, NHL
Chronic myeloid leukemia
Multiple Myeloma

31 (61%)
11 (21%)
08 (16%)
01 (02%)
Stem cell source
Peripheral blood
Bone marrow

39 (77%)
12 (23%)
Intensity Conditioning
Myeloablative
Reduced Intensity Regimen/Nonmyeloablative

42 (82%)
09 (18%)
GVHD prophylaxis
Cyclosporine + Methotrexate
Cyclosporine + Mycophenolate mofetil

46 (90%)
05 (10%)
Days to GVHD onset (Median)
Acute GVHD (range)
Chronic GVHD (range)

40 (18-70)
178 (117-270)
Acute GVHD
No
Yes

28 (55%)
23 (45%)
Chronic GVHD
No
Yes

20 (39%)
31 (61%)
Onset acute GVHD grade
Grade I
Grade II
Grade III-IV

02 (09%)
11 (48%)
10 (43%)
Onset chronic GVHD grade
Mild
Moderate
Severe

03 (10%)
05 (16%)
23 (74%)
Organ target at acute GVHD onset
Skin only
Gut only
Liver only
Skin + gut/liver

01 (04%)
0 (0.0%)
0 (0.0%)
22 (96%)
Organ target at chronic GVHD onset
Skin
Eyes
Mouth
Gastrointestinal tract
Liver
Lung
Joints or fascia

25 (81%)
13 (42%)
26 (84%)
16 (52%)
15 (48%)
5 (16%)
4 (13%)

AML: Acute Myeloid Leukaemia; ALL: Acute Lymphoid Leukaemia; ABL: Acute Biphenotypic Leukaemia; MDS: Myelodysplastic Syndrome; HL: Hodgkin Lymphoma; NHL: Non-Hodgkin's Lymphoma; GVHD: Graft-Versus Host Disease.